Global Proton Pump Inhibitors Market is Expected to be Worth US$ 2.9 Billion, Growing at a CAGR of 4.30% Over The Forecast Period (2020-2027) in 2020
 |
| Proton Pump Inhibitors |
Proton pump inhibitors are drugs that are used to reduce stomach acid levels for a long time in people who have gastroesophageal reflux disease, hyperacidity, or ulcers. In acidic environments, Proton Pump Inhibitors Market are given in an inactive form that is lipophilic in nature and readily crosses cell membranes into intracellular compartments like the parietal cell canaliculus. The inactive drug is protonated and rearranged into its active form, which irreversibly blocks the gastric proton pump of the gastric parietal cells.
Obesity is becoming more common in adults and adolescents, leading to a variety of gastroesophageal reflux disease complications such as Barret's oesophagus (BE), esophageal erosions, and esophageal adenocarcinoma. According to a 2017 report published by the US National Library of Medicine, people with a higher BMI have a higher risk of gastrointestinal diseases like gastroesophageal reflux disease, which can lead to esophageal erosions.
Furthermore, factors such as the rising prevalence of gastrointestinal diseases like duodenal ulcers, barrets oesophagus, and non-erosive reflux disease (NERD) are expected to propel the Global Proton Pump Inhibitors Market forward. In the United States, more than 60% of people have non-erosive reflux disease (NERD), and 30% of people have barrets oesophagus, according to a report published by the National Library of Medicine in July 2020.
COVID-19 has three main effects on tin: directly affecting production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets. Due to nationwide lockdowns, supply chains and manufacturing activities in India, China, and the United States have been disrupted. While countries such as Saudi Arabia, the United Arab Emirates, Egypt, and others face difficulties in transporting drugs from one location to another.
Furthermore, people who take proton pump inhibitors for a longer period of time are more likely to contract COVID-19 infections. Proton pump inhibitors can increase the risk of COVID-19, according to a National Library of Medicine report published in August 2020. Furthermore, people who take proton pump inhibitors twice a day are more likely to contract COVID-19. These factors are limiting the global Proton Pump Inhibitors Market growth. As a result, the COVID-19 pandemic has had a negative impact on the global market for proton pump inhibitors.
Comments
Post a Comment